Oxford Biomedica (OXB) a leading gene and cell therapy group has announced preliminary results for the year ended 31 December 2018.
The company generated revenues of £66.8 million compared to £37.6 million in the previous year, an increase of 78%. The company also reported an Operating EBITDA of £13.4 million and a Profit before tax of £5m as opposed to largely losses in 2017.
John Dawson, Chief Executive Officer of Oxford Biomedica, said: “Oxford Biomedica is at the centre of a burgeoning industry in which life-changing, curative treatment has become a therapeutic reality.
In the past year, alongside landmark regulatory approvals and launches in the sector, we have seen our strategy delivering with significant revenue-generating deals for both our platform and our products, and we continue to scale our capacity to meet the expected demand from future growth.
We are confident that our focus on platform development, pipeline enhancement, technology innovation and operational delivery puts us on the right trajectory to capitalise on our market-leading position.”
Oxford BioMedica is based across several locations in Oxfordshire and now employs more than 430 people.
